Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs.
暂无分享,去创建一个
R. Pieters | A. Veerman | G. Kaspers | E. V. van Wering | R Pieters | G. Kaspers | G J Kaspers | C H Van Zantwijk | E R Van Wering | A Van Der Does-Van Den Berg | A J Veerman | C. V. van Zantwijk | A. van der Does-van den Berg | C. Zantwijk | E. Vanwering | E. R. Van | Wering | A. Van Der Does-Van | Den Berg
[1] J. Ritter,et al. Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) , 1987 .
[2] R. Pieters,et al. DRUG SENSITIVITY ASSAYS IN LEUKAEMIA AND LYMPHOMA , 1990, British journal of haematology.
[3] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[4] R. Pieters,et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. , 1995, Blood.
[5] K. Somberg,et al. Acute tumor lysis syndrome after intrathecal methotrexate administration , 1991, Cancer.
[6] R. Pieters,et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. , 1997, Blood.
[7] R. Pieters,et al. IN VITRO RESISTANCE TO CYTOSINE ARABINOSIDE, NOT TO DAUNORUBICIN, IS ASSOCIATED WITH THE RISK OF RELAPSE IN DE NOVO ACUTE MYELOID LEUKAEMIA , 1996, British journal of haematology.
[8] R. Pieters,et al. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. , 1993, Leukemia.
[9] D. Duval,et al. Heterogeneity of the in vitro responses to glucocorticoids in acute leukemia. , 1980, Cancer research.
[10] Y. Bertrand,et al. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Pieters,et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions , 1990 .
[12] J. Baxter,et al. Tissue effects of glucocorticoids. , 1972, The American journal of medicine.
[13] R. Pieters,et al. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report. , 1994, Leukemia.
[14] M. Cline,et al. Prediction of in vivo cytotoxicity of chemotherapeutic agents by their in vitro effect on leukocytes from patients with acute leukemia. , 1968, Cancer research.
[15] R. Pieters,et al. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. , 1995, Leukemia & lymphoma.
[16] R. Pieters,et al. Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. , 1997, Critical reviews in oncology/hematology.
[17] R. Pieters,et al. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. , 1988, Cancer letters.
[18] S. Iacobelli,et al. Clinical implications of glucocorticoid receptor studies in childhood acute lymphoblastic leukemia. , 1980, Blood.
[19] H. Gralnick,et al. The Morphological Classification of Acute Lymphoblastic Leukaemia: Concordance among Observers and Clinical Correlations , 1981, British journal of haematology.
[20] L. Smets,et al. Prognostic implication of hyperdiploidy as based on DNA flow cytometric measurement in childhood acute lymphocytic leukemia--a multicenter study. , 1987, Leukemia.
[21] A. Ho,et al. Therapeutic and prognostic implications of glucocorticoid receptors and terminal deoxynucleotidyl transferase in acute leukemia. , 1982, Leukemia research.
[22] R. Pieters,et al. Drug combination testing in acute lymphoblastic leukemia using the MTT assay. , 1995, Leukemia research.
[23] R. Pieters,et al. Glucocorticoid resistance in childhood leukemia. , 1994, Leukemia & lymphoma.
[24] B. Chabner,et al. ALTERED PLASMA PHARMACOKINETICS OF METHOTREXATE ADMINISTERED INTRATHECALLY , 1975, The Lancet.
[25] Dedrick Rl,et al. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. , 1977 .
[26] M. Schrappe,et al. Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. , 1987, Haematology and blood transfusion.
[27] R. Pieters,et al. In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. , 1995, Leukemia.
[28] R. Pieters,et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia , 1991, The Lancet.
[29] J. V. van Dongen,et al. Contribution of electron microscopy to the classification of minimally differentiated acute leukemias in children. , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[30] M. Gobbi,et al. Glucocorticoid receptor and in vitro sensitivity to steroid hormones in human lymphoproliferative diseases and myeloid leukemia , 1982, Cancer.
[31] M. Schrappe,et al. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D.,et al. Regression Models and Life-Tables , 2022 .
[33] M. Lippman,et al. Clinical implications of glucocorticoid receptors in human leukemia. , 1978, Cancer research.
[34] R. Pieters,et al. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. , 1991, British Journal of Cancer.
[35] R. Pieters,et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. , 1994, British Journal of Cancer.
[36] J H Goldie,et al. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.
[37] R. Dedrick,et al. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. , 1977, Cancer treatment reports.
[38] R. Pieters,et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. , 1995, Blood.
[39] R. Pieters,et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. , 1998, Blood.